Business
‘Not for the faint-hearted’: COVID crisis brings boom time for biotechs – Sydney Morning Herald
The pandemic has put the focus on Australia’s biotech sector where high risk, high reward is par for the course and regulators can make or break a company.
Normal text sizeLarger text sizeVery large text size
Mesoblast boss and major shareholder Silviu Itescu wont be the only one breathing easier now that the ASX-listed biotechs flagship treatment has managed to get the green light from the US regulators advisory committee.
It was a close run thing by all accounts and for Itescu and investors in Mesoblast a no vote would have seen a decades worth of work come to a standstill.
For his part, Itescu says he wasnt quite as spooked as investors by si…
-
General18 hours agoRestaurants on the brink as business failures plateau
-
General22 hours agoIsraeli forces open fire towards diplomatic delegation touring Jenin in the northern West Bank
-
General18 hours agoRegional house price growth outstrips capital cities
-
General15 hours agoCharlotte McConaghy calls for climate change action in new novel Wild Dark Shore